Article Dans Une Revue Rheumatology Année : 2021

Significance of Sjögren’s syndrome and anti-cN1A antibody in myositis patients

Dan Lévy
  • Fonction : Auteur
  • PersonId : 1130313
Benoit Nespola
  • Fonction : Auteur
Margherita Giannini
  • Fonction : Auteur
Renaud Felten
Coralie Varoquier
  • Fonction : Auteur
Marina Rinagel
  • Fonction : Auteur
Thierry Martin
  • Fonction : Auteur
  • PersonId : 1115885
  • IdRef : 060151013
Vincent Poindron
  • Fonction : Auteur
François Maurier
  • Fonction : Auteur
Haitham Chereih
  • Fonction : Auteur
Bastien Bouldoires
  • Fonction : Auteur
Baptiste Hervier
  • Fonction : Auteur
Cédric Lenormand
Emmanuel Chatelus
Bernard Geny
Jean Sibilia
Laurent Arnaud
  • Fonction : Auteur
  • PersonId : 1075983
  • IdRef : 163893977
Jacques-Eric Gottenberg

Résumé

Objective We recently recorded a high prevalence of inclusion body myositis (IBM) in patients with Sjögren’s syndrome (SS). Whether myositis patients with SS differ from myositis patients without SS in terms of the characteristics of the myositis is currently unknown. Anti-cytosolic 5′-nucleotidase 1 A (cN1A) has recently been proposed as a biomarker for IBM but is also frequent in SS. Whether anti-cN1A is independently associated with IBM is still an open question. We aimed to assess the significance of SS and anti-cN1A in myositis patients. Methods Cumulative data on all myositis patients (EULAR/ACR 2017 criteria) screened for SS (ACR/EULAR 2016 criteria) in a single centre were analysed. Ninety-nine patients were included, covering the whole spectrum of EULAR/ACR 2017 myositis subgroups and with a median follow-up of 6 years (range 1.0–37.5). The 34 myositis patients with SS (myositis/SS+) were compared with the 65 myositis patients without SS (myositis/SS-). Results IBM was present in 24% of the myositis/SS+ patients vs 6% of the myositis/SS- group (P = 0.020). None of the IBM patients responded to treatment, whether they had SS or not. Anti-cN1A was more frequent in myositis/SS+ patients (38% vs 6%, P = 0.0005), independently of the higher prevalence of IBM in this group (multivariate P value: 0.02). Anti-cN1A antibody specificity for IBM was 0.96 (95% CI: 0.87, 0.99) in the myositis/SS- group but dropped to 0.70 (95% CI: 0.48, 0.85) in the myositis/SS+ group. Interpretation In myositis patients, SS is associated with IBM and with anti-cN1A antibodies, independently of the IBM diagnosis. As a consequence, anti-cN1A has limited specificity for IBM in myositis patients with SS.

Fichier non déposé

Dates et versions

hal-03608608 , version 1 (14-03-2022)

Identifiants

Citer

Dan Lévy, Benoit Nespola, Margherita Giannini, Renaud Felten, François Severac, et al.. Significance of Sjögren’s syndrome and anti-cN1A antibody in myositis patients. Rheumatology, 2021, ⟨10.1093/rheumatology/keab423⟩. ⟨hal-03608608⟩
65 Consultations
0 Téléchargements

Altmetric

Partager

  • More